Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

TSXV:ARCH - Post Discussion

Arch Biopartners Inc > This is great.
View:
Post by stocksarefun on Nov 03, 2021 2:58pm

This is great.

Are we at the point where we should try and broadcast this ticker across other networks beyond Stockhouse? Surprised we still have no mentions at all on Reddit in the last 200 days, and no stocktwits page. 

Do the floodgates actually open when Phase 3 is announced? I have very little experience with phase 2 to phase 3 progression for biotechs in Canada.

How are you all feeling about this well kept secret?
Comment by Antonius2 on Nov 03, 2021 3:42pm
Treatments that have been shown to work in phase II clinical trials must succeed in one more phase before they're approved for general use. Phase III clinical trials compare the safety and effectiveness of the new treatment against the current standard treatment.  Since there is no current standard treatment for AKI - expect a sudden and very pronounced interest in the Arch drug ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities